Shirley Lewis1, Supriya Chopra Sastri2, Supreeta Arya3, Shaesta Mehta4, Prachi Patil4, Shyamkishore Shrivastava5, Reena Phurailatpam2, Shailesh V Shrikhande6, Reena Engineer2. 1. Department of Radiotherapy and Oncology, Kasturba Medical College, MAHE, Manipal, India. 2. Department of Radiation Oncology, Tata Memorial Centre, Mumbai, India. 3. Department of Radiology, Tata Memorial Centre, Mumbai, India. 4. Department of Gastroenterology, Tata Memorial Centre, Mumbai, India. 5. Department of Radiation Oncology, Apollo Hospitals, Navi Mumbai, India. 6. Department of Surgical Oncology, Tata Memorial Centre, Mumbai, India.
Abstract
BACKGROUND: We report the response and outcomes of borderline resectable and locally advanced pancreatic cancer (BRPC & LAPC) patients treated with dose escalated neoadjuvant intensity modulated radiotherapy (IMRT). METHODS: Thirty newly diagnosed patients with BRPC (n=18) and LAPC (n=12) (NCCN criteria V 2.2.12) were accrued in this prospective study from 2008-2011. All patients received neoadjuvant chemoradiation (NACRT) using Helical Tomotherapy (dose of 57 Gy over 25 fractions to the gross tumor volume (GTV) and 45 Gy over 25 fractions to suspected microscopic extension) along with weekly gemcitabine. RESULTS: Fifteen patients (50%) had a partial response. A complete metabolic response (CMR) on PET was seen in 9 patients (30%). Among BRPC, 9 patients (50%) were surgically explored and 7 underwent R0 resection (39%). The median follow up of surviving patients was 85 [interquartile range (IQR): 64.5-85.8] months. The median progression free survival (PFS) was 13 months for BRPC and 8.8 months for LAPC. The median overall survival (OS) was 17.3 months for BRPC and 11.8 months for LAPC. Among patients undergoing R0 resection, the median PFS and OS was 27 and 35.5 months respectively. CONCLUSIONS: Dose escalated radiotherapy with concurrent chemotherapy is feasible and can downsize some tumors resulting in surgery in about 39% of the BRPC.
BACKGROUND: We report the response and outcomes of borderline resectable and locally advanced pancreatic cancer (BRPC & LAPC) patients treated with dose escalated neoadjuvant intensity modulated radiotherapy (IMRT). METHODS: Thirty newly diagnosed patients with BRPC (n=18) and LAPC (n=12) (NCCN criteria V 2.2.12) were accrued in this prospective study from 2008-2011. All patients received neoadjuvant chemoradiation (NACRT) using Helical Tomotherapy (dose of 57 Gy over 25 fractions to the gross tumor volume (GTV) and 45 Gy over 25 fractions to suspected microscopic extension) along with weekly gemcitabine. RESULTS: Fifteen patients (50%) had a partial response. A complete metabolic response (CMR) on PET was seen in 9 patients (30%). Among BRPC, 9 patients (50%) were surgically explored and 7 underwent R0 resection (39%). The median follow up of surviving patients was 85 [interquartile range (IQR): 64.5-85.8] months. The median progression free survival (PFS) was 13 months for BRPC and 8.8 months for LAPC. The median overall survival (OS) was 17.3 months for BRPC and 11.8 months for LAPC. Among patients undergoing R0 resection, the median PFS and OS was 27 and 35.5 months respectively. CONCLUSIONS: Dose escalated radiotherapy with concurrent chemotherapy is feasible and can downsize some tumors resulting in surgery in about 39% of the BRPC.
Entities:
Keywords:
Pancreatic cancer; borderline resectable pancreatic cancer (BRPC); intensity modulated radiotherapy (IMRT); locally advanced pancreatic cancer (LAPC)
Authors: Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess Journal: JAMA Date: 2007-01-17 Impact factor: 56.272
Authors: Skye C Mayo; Marta M Gilson; Joseph M Herman; John L Cameron; Hari Nathan; Barish H Edil; Michael A Choti; Richard D Schulick; Christopher L Wolfgang; Timothy M Pawlik Journal: J Am Coll Surg Date: 2011-11-04 Impact factor: 6.113
Authors: Matthew H G Katz; Jason B Fleming; Priya Bhosale; Gauri Varadhachary; Jeffrey E Lee; Robert Wolff; Huamin Wang; James Abbruzzese; Peter W T Pisters; Jean-Nicolas Vauthey; Chusilp Charnsangavej; Eric Tamm; Christopher H Crane; Aparna Balachandran Journal: Cancer Date: 2012-05-17 Impact factor: 6.860
Authors: Jordan M Winter; Murray F Brennan; Laura H Tang; Michael I D'Angelica; Ronald P Dematteo; Yuman Fong; David S Klimstra; William R Jarnagin; Peter J Allen Journal: Ann Surg Oncol Date: 2011-07-15 Impact factor: 5.344
Authors: Christine A Iacobuzio-Donahue; Baojin Fu; Shinichi Yachida; Mingde Luo; Hisashi Abe; Clark M Henderson; Felip Vilardell; Zheng Wang; Jesse W Keller; Priya Banerjee; Joseph M Herman; John L Cameron; Charles J Yeo; Marc K Halushka; James R Eshleman; Marian Raben; Alison P Klein; Ralph H Hruban; Manuel Hidalgo; Daniel Laheru Journal: J Clin Oncol Date: 2009-03-09 Impact factor: 44.544
Authors: Michael D Chuong; Gregory M Springett; Jessica M Freilich; Catherine K Park; Jill M Weber; Eric A Mellon; Pamela J Hodul; Mokenge P Malafa; Kenneth L Meredith; Sarah E Hoffe; Ravi Shridhar Journal: Int J Radiat Oncol Biol Phys Date: 2013-04-05 Impact factor: 7.038
Authors: Minsig Choi; Lance K Heilbrun; Raghu Venkatramanamoorthy; Jawana M Lawhorn-Crews; Mark M Zalupski; Anthony F Shields Journal: Am J Clin Oncol Date: 2010-06 Impact factor: 2.339
Authors: Somnath Mukherjee; Christopher N Hurt; John Bridgewater; Stephen Falk; Sebastian Cummins; Harpreet Wasan; Tom Crosby; Catherine Jephcott; Rajarshi Roy; Ganesh Radhakrishna; Alec McDonald; Ruby Ray; George Joseph; John Staffurth; Ross A Abrams; Gareth Griffiths; Tim Maughan Journal: Lancet Oncol Date: 2013-03-06 Impact factor: 41.316
Authors: Priyanka Gupta; Stella Totti; Pedro A Pérez-Mancera; Eleanor Dyke; Andrew Nisbet; Giuseppe Schettino; Roger Webb; Eirini G Velliou Journal: RSC Adv Date: 2019-12-17 Impact factor: 4.036